Company intelligence / Profile preview

MacuCLEAR

Richardson, Texas, United Statesarchive.constantcontact.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

MacuCLEAR developed a novel topical small molecule therapy (MC‑1101) to treat and slow progression of dry age-related macular degeneration by improving ocular blood flow. The active ingredient in MC‑1101 had prior FDA approval as an oral antihypertensive. Clinical results included a successful Phase Ib proof-of-concept study and initiation of Phase II/III trials. The company also pursued additional compounds for diabetic retinopathy and other retinal vascular diseases. In May 2010, MacuCLEAR was acquired by Healthcare of Today.

Therapeutic areas: Ophthalmology
Modalities: Small moleculeTopical drug delivery
Industry: Biotech

Drug pipeline

1 asset

MC-4001

Preclinical

Beyond the preview

Go deeper on MacuCLEAR.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MacuCLEAR.

Explore the full profile